New drug duo aims to control advanced colon cancer
NCT ID NCT06268015
First seen Feb 05, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study tests two immunotherapy drugs, botensilimab and balstilimab, in 16 people with advanced colorectal cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors. If the cancer progresses, standard chemotherapy is added. Participants are followed for up to 2 years to monitor safety and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.